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More than 2(0 years have passed since the National High
Blood Pressure Education Program was established and its
initial report on the detection, evaluation and treatment of
patients with hypertension was released . In those days, on
the basis of an arbitrary definition of hypertension as dia-
stolic pressure > i04 mm Hg, 23 million Americans were
estimated to have essential hypertension . In addition, in
response to the initial results of the Veterans Administration
Cooperative Studies, a stepped care algorithm of antihyper-
tensive therapy was proposed . This approach, now consid-
ered to be one of therapeutic empiricism, recommended that
antihypertensive therapy be initiated with a thiazide diuretic
agent (for example, hydrochlorothiazide, 50 mg twice daily)
followed, if necessary, by successive therapeutic steps in-
cluding an adrenergic inhibitor (step 2 : reserpine, for exam-
ple); a direct-acting smooth muscle relaxing vasodilator (step
3: hydralazine, for example), and a more potent agent (step
4: guanethidine or minoxidil, for example) . Ir. reality, this
concept was not at all empiric but founded otn physiologic
knowledge . Thus, if therapy was initiated by any of the other
agents (in step 2, 3, or 4), the initial pressure reduction would
soon be attenuated as a result of intravascular volume
expansion (or "pseudotolerance") . Moreover, because the
diuretic drug would be effective in approximately 50% or
more of patients, its use as an initial therapeutic step was
reasonable and doses of possible subsequent medications
could be reduced, thereby diminishing chances of associated
side effects .
This concept soon caught hold and, over the ensuing
years, a dramatic reduction in deaths from stroke, coronary
heartn disease and overall cardiovascular diseases resulted
.
With the report of the Hypertension Detection and Follow-Up
Program, definition of hypertension was modified to include
all patients whose diastolic pressure exceeded 89 mm Hg,
thereby increasing the number of patients with hypertension
to upward of 59 million Americans . In the subsequent
reports of the Joint National Committee (JNC) on Detection,
Evaluation, and Treatment of High Blood Pressure, the
beta-adrenergic receptor blocking agent was suggested as an
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alternative "first step" agent, to be prescribed (as with diuretic
agents) in submaximal doses and later, if necessary, in full
doses. With JNC-Ill, nonpharntacologic therapy was intro-
duced, and other concepts such as step-down therapy and
evaluation forother cardiovascular risk factors were encour-
aged. In JNC-111, the angiotensin-converting enzyme (ACE)
inhibitors and 'alcium antagonists were included among the
initial therapeutic options . This broader spectrum of agents
also permitted a more individualized selection of therapy
based on certain clinical and demographic characteristics.
Over these 20 years of a national hypertension education
program, for health care professions as well as the general
public, continued reductions in morbidity and mortality
ensued: Stroke deaths decreased by >_60% and deaths from
coronary heart disease by almost 50%. Indeed, with the
publication last month of the primary prevention document
on hypertension (1), for the first time the estimated number
of patients with hypertension, defined as blood pressure
>89 mm Hg, has been reduced-by approximately 17%-to
50 million Americans .
Accompanying this primary prevention document was
the publication of JNC-V, which has once again underscored
the dramatic and continued evolution of our concepts about
hypertensive disease and antihypertensive therapy (2) .
Among
	
changes are :
1 . Description of a new staging of the severity
of hyper-
tensive disease that excludes the term mild hypertension
.
2. Inclusion of systolic pressure elevations in
this severity
staging of hypertensive disease .
3. An expanded section on the evaluation of patients
with
hypertension to include manifestations of target organ in-
volvement; situations for use of noninvasive,
automated
ambulatory blood pressure monitoring devices
; further sig-
nificance of laboratory tests and diagnostic procedures and
more recent concepts on community blood pressure
control
programs.
4. Because of current concerns about
health care eco-
nomics, there is greater discussion of the cost of care and
strategies related to the long-term follow-up of patients with
hypertension.
5. The concept of nonpllalmacologic
approaches to the
management of hylertension was modified
to that of life-
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style changes, now including exercise as an antihypertensive
modality .
6. Initial drug therapy options were expanded to include
alpha,- and alpha-beta-adreaergic receptor blocking agents .
7. In considering th=s broader option of initial therapies,
the document indicates that the "diuretics and beta-blockers
are preferred because a reduction in morbidity and mortality
has been demonstrated" and that the other initial options
that include "the ACE inhibitors, calcium antagonists,
alpha
;- and alpha-beta adrenergie receptor blockers have not
been tested or shown to reduce morbidity and mortality."
This concept was deemed appropriate in view of recent
reports on the efficacy of antihypertensive therapy in several
multicenter trials involving elderly patients. However, since
submission of this consensus report, other multicentor trials,
using compounds from the latter classes of agents, have
shown a reduction in morbidity and mortality in normoten-
sive cardiovascular patients .
8. Because the recent expansion of knowledge concerning
treatment of special populations of patients with hyperten-
sion also includes patients with special demographic charac-
teristics and coexisting diseases, the section on individual-
ized antihypea tensive therapy has been considerably
expanded .
9. The foregoing special situations encompass other con-
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siderations including hypertension in women, isolated sys-
tolic hypertension in the elderly, hypertension associated
with cyclosporine, shock wave renal lithotripsy, cocaine and
erythropoietin-induced -hypertension .
10 . harmacologic tables were updated to include new
drugs and drug classes, mechanisms of drug action, drug-
drug interactions and drugs to be used in hypertensive crises
and refractory hypertension .
All in all, there has been a tremendous evolution in the
recommendations of the Joint National Committee and this
is clear with its fifth consensus report. Should a reprint of
this report be of interest, please direct your requests for
reprints to the High Blood ressure Education rogram,
National Heart, Lung, and Blood Institute, National Insti-
tutes of Health, Building 31, oom 4A05, Bethesda, Mary-
land 20892 .
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